Geriatric Medicine Development Market - Global Industry Analysis and Strategy - PowerPoint PPT Presentation

Loading...

PPT – Geriatric Medicine Development Market - Global Industry Analysis and Strategy PowerPoint presentation | free to download - id: 7ebb49-YWRiO



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Geriatric Medicine Development Market - Global Industry Analysis and Strategy

Description:

More than 50% of prescriptions is written for people aged 65 years and older. Many older people suffer from comorbid conditions and one in three takes at least five drugs or more on a daily basis. This significantly increases the risk of Adverse Drug Events (ADEs) and hospitalization. Enquiry about report: – PowerPoint PPT presentation

Number of Views:12

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Geriatric Medicine Development Market - Global Industry Analysis and Strategy


1
Geriatric Medicine Development - Carving out New
Opportunities to Treat Age-related Diseases
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
TELEPHONE 1 (503) 894-6022E-MAIL
sales_at_researchbeam.com
Published on Oct 2014
2


Report Overview
  • The biosimilars market is undergoing rapid change
    with developments such as the recent approvals of
    infliximab and trastuzumab heralding a new era.
  • More than 50 of prescriptions is written for
    people aged 65 years and older. Many older people
    suffer from comorbid conditions and one in three
    takes at least five drugs or more on a daily
    basis. This significantly increases the risk of
    Adverse Drug Events (ADEs) and hospitalization.
    Up to one third of emergency admissions in
    elderly people is drug-related.
  • There remains a lack of clinical data to support
    prescription decisions as relatively few
    medicines have been clinically evaluated in
    age-appropriate patients. In addition, many drugs
    are not available in formulations that are
    suitable for the elderly, leading to
    non-compliance and lack of therapeutic efficacy.
    In 2011, the EMA introduced its Geriatric
    Medicines Strategy to ensure that the medical
    requirements of older people are identified
    earlier in the drug development process. In 2012,
    the ICH E7 guidelines were revised to include a
    greater focus on involving more geriatric
    patients in drug trials.
  • Read More At http//www.researchbeam.com/geriatr
    ic-medicine-development-carving-out-new-opportunit
    ies-to-treat-age-related-diseases-market

3


Report Overview
  • Scope
  • Reviews the current regulatory landscape and
    helps sponsors to understand the potential impact
    of recent guidelines.
  • Assesses the barriers to entry in geriatric
    medicines and identifies potential ways to
    overcome them and improve clinical decision
    making.
  • Evaluates the importance of establishing Target
    Quality Product Profiles (TQPP) to help sponsors
    determine the target patient population earlier
    on in drug development.
  • Identifies treatment gaps and commercial
    opportunities based on primary care real-time
    data and KOL insights.
  • - Analyses different strategies to develop
    age-appropriate medicines in niche therapeutic
    fields and discusses methods to encourage the
    smarter prescription of medicines.

4


Table of Content
Executive SummaryMethodologyGeriatric
medicines an overviewEmerging issuesUnmet
clinical needsCurrent landscapeRegulatory
environmentPolitical will for changeStrategic
considerations for developing geriatric
medicinesBarriers to developing geriatric
drugs Clinical trial considerationsâœBig
dataâsâ
About PowerShow.com